St. Jude Medical announced the resumption of the company’s US IDE trial evaluating the Portico Transcatheter Aortic Valve Implantation System.
The Portico IDE trial originally launched in May 2014, and is designed to support US approval of the Portico system.
The approval follows a comprehensive review of the Portico system by the U.S. Food and Drug Administration (FDA) after St. Jude Medical temporarily paused implants of the valve worldwide in September 2014.
The company decided to pause implants due to reports of reduced leaflet motion observations in patients implanted with Portico within the IDE study. The observation was subsequently identified in the study’s control arm, which consisted of commercially-available TAVR valves.
St. Jude Medical’s review found no excess rate of clinical events associated with the leaflet motion observation. The company’s findings were then confirmed by independent reviews, which found reduced leaflet mobility is a class effect, present in TAVR and surgical valves across the industry.
The data also confirmed that the observation is not linked to excess adverse clinical events, has not been shown to impact valve clinical performance and can be resolved by medical therapy.
"We are excited to resume our U.S. IDE trial, which is a critical step toward providing the Portico valve to more patients in need," said Dr. Mark Carlson, chief medical officer for St. Jude Medical.
Aortic stenosis is the third most prevalent form of cardiovascular disease in the Western world after hypertension and coronary artery disease.
The Portico system was developed to simplify TAVR procedures for physicians by improving control, ease of use and accuracy over other commercially-available TAVR valves.
The system also offers the ability to be fully recaptured and repositioned prior to full deployment and release from the delivery system, allowing physicians to obtain optimal placement to improve patient outcomes.